License Agreement - HEScGRO

Stem Cell Sciences plc
25 January 2007


25 January 2007

   Millipore's HEScGRO(TM) Medium Advances Human Embryonic Stem Cell Research

As a direct result of an agreement between Millipore and Stem Cell Sciences,
announced in October 2006, Millipore Corporation have today announced the
availability of HEScGRO animal component-free medium for human embryonic 
stem cell research.

HEScGRO medium is the first commercially available animal component-free medium
tested successfully for human embryonic stem cell culture and shown to maintain
hES cells in their undifferentiated state. The agreement between Millipore and
Stem Cell Sciences signed in October 2006 made it possible for Millipore to
manufacture and market SCS' serum-free media with SCS receiving royalties from
all future sales of HEScGRO.

HEScGRO's unique serum-free, ready-to-use and complete formulation offers new
ease and reliability in growing human embryonic stem cells. Media containing
animal-derived components are subject to wide variability and may contain
factors that promote differentiation of hES cells,as well as containing toxic
proteins or immunogens that can adversely affect the cells themselves, HEScGRO
medium is a defined, animal component-free formulation that successfully
addresses these problems and allows scientists to grow human stem cells with
confidence.

Commenting on the availability of HEScGRO, David Dodd, Chairman of Stem Cell
Sciences, said:

"We're very pleased with this agreement with Millipore Corporation and look
forward to the success of this unique new product."

                                     - Ends-

For further information, please contact:
Stem Cell Sciences plc
David Dodd, Non-Executive Chairman of Stem Cell Sciences
Hugh Ilyine, Vice President and Chief Operating Officer            0131 662 9829

Weber Shandwick Financial
Louise Robson 
James White                                                        020 7067 0700

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,
established in Melbourne, Australia in 1994, providing products in the
burgeoning stem cell research and drug discovery markets, in addition to the
targeted development of cell-based therapies for neurodegenerative disease and
injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics. SCS
principal focus is in neurological disease. Revenues in the neurotech market,
including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110
billion (Neurotech Insights, Volume 2/3 April 30 2006).

SCS operates as a group of independent operations with laboratories in Scotland,
Japan and Australia, each of which is affiliated with an academic centre of
excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,
UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem
Cell Centre, Melbourne, Australia.

SCS has four business units focused on key sustainable business strategies.

SC Proven(R) provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon, part of
Millipore Corporation.

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.

SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.

SC Therapies' goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is conducting preclinical evaluations of its
neural stem cell lines in a number of therapeutic applications. The first
preclinical programme is being undertaken by SCS' Japanese affiliate, which
recently announced the exclusive licensing of human multi-potent adipose-derived
stem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinical
studies for the treatment of Duchenne Muscular Dystrophy in 2007-8.

For further information on the company please visit:
www.stemcellsciences.com

About Millipore
Millipore is a leading provider of products and services that improve
productivity in laboratory research and bioprocessing manufacturing sites.
Through its broad product portfolio, the Company drives growth through
innovation and delivers higher value-added applications to the marketplace.
Millipore experts have a comprehensive understanding of customers' research,
which results in superior tools, technologies and services. The Company is part
of the S&P 500 index and employs approximately 5,800 employees in more than 47
offices worldwide. For additional information on Millipore Corporation, please
visit www.millipore.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange